<SEC-DOCUMENT>0001104659-21-005017.txt : 20210119
<SEC-HEADER>0001104659-21-005017.hdr.sgml : 20210119
<ACCEPTANCE-DATETIME>20210119082246
ACCESSION NUMBER:		0001104659-21-005017
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210119
FILED AS OF DATE:		20210119
DATE AS OF CHANGE:		20210119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Grifols SA
		CENTRAL INDEX KEY:			0001438569
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35193
		FILM NUMBER:		21534008

	BUSINESS ADDRESS:	
		STREET 1:		1585 BROADWAY
		STREET 2:		SUITE 2376
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-969-3335

	MAIL ADDRESS:	
		STREET 1:		1585 BROADWAY
		STREET 2:		SUITE 2376
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm213541d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN ISSUER<BR>
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month January&nbsp;2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission File No.&nbsp;001-35193)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Grifols, S.A.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Avinguda de la Generalitat, 152-158</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Parc de Negocis Can Sant Joan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sant Cugat del Valles 08174</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Barcelona, Spain</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of registrant&rsquo;s principal
executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;20-F <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT>&nbsp;
Form&nbsp;40-F <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T Rule&nbsp;101 (b)&nbsp;(1):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;
No <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T Rule&nbsp;101 (b)&nbsp;(7):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;
No <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant by furnishing
the information contained in this Form&nbsp;is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b)&nbsp;under
the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes <FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;
No <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule&nbsp;12g3-2(b): 82-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Grifols, S.A.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Item</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Sequential&nbsp;Page&nbsp;Number</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 63pt; text-indent: -45pt">&nbsp;</TD>
    <TD STYLE="padding-left: 63pt; text-indent: -45pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 63pt; text-indent: -45pt; width: 5%">1.</TD>
    <TD STYLE="padding-left: 63pt; text-indent: -45pt"><U>Other Relevant Information, dated January&nbsp;19, 2021</U></TD>
    <TD STYLE="width: 1%"></TD>
    <TD STYLE="text-align: right; width: 1%">3</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 75%">&nbsp;<IMG SRC="tm213541d1_6kimg01.jpg" ALT="" STYLE="vertical-align: top"></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Grifols, S.A.</B></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Parc Empresarial Can Sant Joan</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Avda Generalitat n&ordm; 152-158</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">08174 SANT CUGAT DEL VALLES</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">ESPA&Ntilde;A</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Tel (34) 935 710 500</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Fax (34) 935 710 267</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grifols, S.A. (&quot;<B>Grifols</B>&quot;),
in accordance with the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative
Royal Decree 4/2015, of 23 October, reports the following</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>OTHER RELEVANT INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GRIFOLS reproduces the text of the Press
Release that it sent to the media regarding the medical trial with a new medicine to treat COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&quot;<B>Grifols begins
clinical trial of a new medicine that would provide immediate immunity against COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.25in"><B>&nbsp;</B></TD>
    <TD STYLE="width: 0.25in"><B>&nbsp;</B><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><B>The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization
    due to the progression of the disease and complementing the vaccine in the early phase after vaccination</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><B>The medicine, an anti-SARS-CoV-2 immunoglobulin, given subcutaneously, would provide immediate protection after exposure
    to the virus and could be used to protect the elderly and healthcare workers. It could also be given to immunocompromised
    patients for whom the vaccination isn&rsquo;t indicated</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><B>The treatment is based on the Grifols immunoglobulin Gamunex&reg;-C, and contains anti-SARS-COV-2 polyclonal antibodies
    from plasma donors who have recovered from COVID-19</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><B>The clinical trial to evaluate the safety and efficacy of the plasma-derived medicine will have doctors Oriol Mitj&agrave;
    and Bonaventura Clotet as the principal researchers and is expected to begin in early 2021</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Barcelona, Spain, January 18, 2021 </B>-
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with
a track record of more than 100 years dedicated to enhancing people&rsquo;s health and well-being, today announced it will begin
a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex&reg;-C
and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new drug would provide immediate post-exposure
protection against the virus and would be especially useful as a complement to the vaccine in the early phase after vaccination.
In addition, it could protect the elderly and healthcare workers as well as immunocompromised patients for whom vaccination isn&rsquo;t
recommended. It could also help contain outbreaks in places where the vaccination hasn&rsquo;t begun or is still underway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grifols expects this clinical trial, led
by the researchers Oriol Mitj&agrave; and Bonaventura Clotet, from Germans Trias i Pujol Hospital in Barcelona, to begin in February
2021, with the possibility of results in the spring.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 75%">&nbsp;<IMG SRC="tm213541d1_6kimg01.jpg" ALT="" STYLE="vertical-align: top"></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Grifols, S.A.</B></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Parc Empresarial Can Sant Joan</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Avda Generalitat n&ordm; 152-158</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">08174 SANT CUGAT DEL VALLES</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">ESPA&Ntilde;A</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Tel (34) 935 710 500</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">Fax (34) 935 710 267</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">About 800 patients, all asymptomatic but
having tested positive for the virus in a diagnostic test, will participate in the clinical study, receiving subcutaneously Grifols&rsquo;
immunoglobulin rich with anti-SARS-CoV-2 antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Grifols immunoglobulin Gamunex&reg;-C,
whether administered intravenously, intramuscularly or subcutaneously, has proven to be safe and efficacious in the prevention
of diverse infectious diseases in immunocompromised patients and has been used for this for more than 15 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Dr. Mitj&agrave;, &ldquo;This
treatment based on immunoglobulins would provide a combination of polyclonal antibodies that, compared with monoclonal antibodies,
offers a greater diversity that could improve the degree of protection against the virus.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Antonio P&aacute;ez, Medical Director
at Grifols, underscores that the potential treatment &ldquo;is easy to refrigerate while its subcutaneous administration facilitates
its distribution and use in any doctor&rsquo;s office, avoiding hospitalizaton. If the new therapy&rsquo;s efficacy is confirmed,
it could be administered to people who test positive for the virus through PCR and antigen tests in hospitals and primary care
offices.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grifols, a global leader in the production
and distribution of immunoglobulins and hyperimmune immunoglobulins, currently has underway more than 25 research initiatives to
treat different stages of COVID-19, from early exposure to the virus to severe cases requiring hospitalization and intensive care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2020, Grifols, together with
other companies and various U.S. health agencies, began the clinical trial ITAC (Inpatient Treatment with Anti-Coronavirus Immunoglobulin)
to evaluate the efficacy and safety of the anti-SARS-CoV-2 hyperimmune globulin in hospitalized and serious cases. Results are
expected during the first half of 2021.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Barcelona, on 19 January 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Nuria Mart&iacute;n Barn&eacute;s</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Secretary to the Board of Directors</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">Grifols,&nbsp;S.A.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ David I. Bell</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="width: 37%">David I. Bell</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Authorized Signatory</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&nbsp; January&nbsp;19, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm213541d1_6kimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm213541d1_6kimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !7 2(# 2(  A$! Q$!_\0
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MH/\ 3(J_L0(RJ_0_UKMXTR_#82O2CAH**<6W;U.7(<35K0FZKO9GX4_M_?\
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M<?EM3'Y/3P]%I.T7KY(\G#8N.'QLJDE?5_J?U]03+(^ ]UT)^9"!^>*^.?\
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M.7O"W_"%Z3X)_:%O)-#UW3[>.RA\3I"TMI>%1@"X5,LCXY,F-K'J17Z11?\
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MO]FZROX'3KG-?9'_  >(N(K_ /9\+?Q?VT3_ -\V5?&O_!ME(#_P6,^&(/\
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ML2C<>N!5'Q#K]MX9T2\U"[FC@L["%KFYE<@+#$@W.Y/H%!/X5R5C^TEX O\
MPBFNVGCCPE<:')'YB:@-5@:V*_W_ # ^W;[YK\G/^"_'_!=#PQ<_"'6O@G\(
MM836=;\4Q&TUC6].E$EK#9D?O%AE0D%FP!P>59O6OSK+<JQ&,KJC3B_-]O4^
MFQ.,IT*;J29^-W[9/QJ_X7_^U;\2_'0#&#Q3K][>VP/41/,YC'X)M'X5_01_
MP:\?L_S_  ?_ ."9MOKMY"8Y_B!KEUK,#$8+VP5+>(_0^3(1Z[ABOPB_X)Y_
ML/\ B/\ ;T_:=T'P+X>LKN;2[FY5]8U'RR8=,A!_>;VZ*Y7<5!ZG%?UP?#'X
M7Z1\%OAKH?A70;:.QT3PY90Z?8V\8P(XXU"*/R'YDU][QOCJ5/#4\NI/73Y)
M:+[_ -#YW(,-.=66)GM_F?S;_P#!SK^\_P""MVOG_J6[ ?\ CE?2O_!G=(%\
M:?&KWT_21_Y'O*^:?^#G0_\ &VWQ"@'/_".6)_\ '*T?^#>;_@J+\*_^"<?B
M7XBO\3)]:LHO%%K8P6366GM<D-#)<,Y8@@ 8E7%=]:A4K<-PIT8MMQCHO5'-
M3G&&:.<W9)O]3^EV%/+B&>PIKS+(NT'DU^<5O_P= _LJVT>5UKQD[9Q\VC.5
M/_C]?:2?M6>$9/V7XOBY/J46F^"[G0AXB6\O"(3':F(2@-D\,5( &>I&*_+L
M1EF,P]O;TW&^UUN?6TL51J75.2=CT=I$,>QF#*>,BN$_:&_9Y\(_M0?"'5/!
MGB[38-7T35H'ADCD4&9<]XV/*M[BOS^_8I_X.A?@Y\>?%6I:+\0PWPVN&U&:
M'2M1O?FTRXMPY$1ED&3 VW!8R )G/S#I7UU\3O\ @JK^SO\ "WP')K^I_&'X
M>WMJL9D@CTG6H+ZYNN,XACA=G=L=E!XK:KE>/PU51G3DI=-/R(CB\/5@VI)H
M_EW_ ."B'[),_P"Q!^VIX[^&5R7*>'KT2:<X/W[26-9H"3W_ ';KGWS7[7_\
M&E/[3^H?%+]DKQQ\-M2DN+E_AAJ=M-932'(2SU 3ND(/^Q+;W!QV$@K\8_\
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@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
